<html>
<head>
<title>Prepared and Filed by St Ives Financial</title>
<!--IMSstiveswithoutIMS-->
</head>
<body bgcolor="#ffffff" style='font-family:"Times New Roman"'>
<page>



<div style="border:none;border-bottom:solid .05em;padding:0in 0in 1.0pt 0in">
<div style=" border:none;border-bottom:solid .25em;padding:0in 0in 1.0pt 0in"><p></p></div></div><BR>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><B><font style='font-size:15PT'>UNITED STATES</font></B></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><B><font style='font-size:15PT'>SECURITIES AND EXCHANGE COMMISSION</font></B></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font style='font-size:10pt'>Washington, D.C. 20549</font></b></p>

<p style=' margin-bottom:0pt; margin-top:12pt;text-align:center;'><B><font style='font-size:16PT'>FORM 8-K</font></B></p>

<p style=' margin-bottom:0pt; margin-top:12pt;text-align:center;'><B><font style='font-size:10PT'>CURRENT REPORT</font></B></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font style='font-size:10pt'>Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934</font></b></p>

<p style=' margin-bottom:0pt; margin-top:12pt;text-align:center;'><font style='font-size:10pt'><b>Date
  of Report (Date of earliest event reported): </b></font><b><font style='font-size:10pt'>December
  20, 2006</font></b></p>

<p style=' margin-bottom:0pt; margin-top:8pt;text-align:center;'><B><font style='font-size:18PT'>BEIJING MED-PHARM CORPORATION</font></B></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font style='font-size:10pt'>(Exact name of registrant specified in its charter)</font></p>
<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font style='font-size:10pt'>&nbsp;</font></p>
<table width="100%" cellspacing=0 cellpadding=0>
    <tr>
        <td width="50">&nbsp;</td>
                    <td align=center valign=top width="280"><b><font style='font-size:10pt'>Delaware</font></b><br>
<font style='font-size:10pt'>(State or other jurisdiction of</font><br>
<font style='font-size:10pt'>incorporation)</font><br></td>
        <td align=center valign=top width="280"><b><font style='font-size:10pt'>000-51409</font></b><br>
            <font style='font-size:10pt'>(Commission File Number)</font><br>
<font style='font-size:10pt'>&nbsp;</font><br></td>
        <td align=center valign=top width="280"><b><font style='font-size:10pt'>20-0434726</font></b><br>
            <font style='font-size:10pt'>(I.R.S. Employer Identification</font><br>
<font style='font-size:10pt'>No.)</font><br></td>
        <td width="50">&nbsp;</td></tr></table>

<table width="100%" cellspacing=0 cellpadding=0>
  <tr>
    <td width="50">&nbsp;</td>
    <td align=center valign=top width="280">&nbsp;</td>
    <td align=center width="280" >&nbsp;</td>
    <td align=center valign=top width="280">&nbsp;</td>
    <td width="50">&nbsp;</td>
  </tr>
  <tr>
    <td width="50">&nbsp;</td>
    <td align=center valign=top width="280"><font style='font-size:10pt'><b>600
      W. Germantown Pike, Suite 400,</b></font><b><br>
      <font style='font-size:10pt'>Plymouth Meeting, Pennsylvania</font></b><br>
      <font style='font-size:10pt'>(Address of principal executive offices)</font><br>
    </td>
    <td align=center width="280" >&nbsp;</td>
    <td align=center valign=top width="280"><font style='font-size:10pt'>&nbsp;</font><br>
      <font style='font-size:10pt'><b>19462</b></font><br>
      <font style='font-size:10pt'>(Zip Code)</font></td>
    <td width="50">&nbsp;</td>
  </tr>
</table>

<p style=' margin-bottom:0pt; margin-top:12pt;text-align:left;'><font style='font-size:10pt'><b>Registrant&#146;s telephone, including area code:</b> </font><b><font style='font-size:10pt'>(610) 940-1675</font></b></p>

<p style=' margin-bottom:0pt; margin-top:8pt; text-indent:5%;text-align:left;'><font style='font-size:10pt'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (</font><i><font style='font-size:10pt'>see</font></i><font style='font-size:10pt'> General Instruction A.2. below):</font></p>

<p style=' margin-bottom:0pt; margin-top:8pt; text-indent:0%;text-align:left;'><img src="emptybox.gif"><font style='font-size:10pt'>
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under
  the Securities Act (17 CFR 230.425)</font></p>

<p style=' margin-bottom:0pt; margin-top:8pt; text-indent:0%;text-align:left;'><img src="emptybox.gif"><font style='font-size:10pt'>
  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under
  the Exchange Act (17 CFR 240.14a-12)</font></p>

<p style=' margin-bottom:0pt; margin-top:8pt; text-indent:0%;text-align:left;'><img src="emptybox.gif"><font style='font-size:10pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
  Act (17 CFR 240.14d-2(b))</font></p>

<p style=' margin-bottom:0pt; margin-top:8pt; text-indent:0%;text-align:left;'><img src="emptybox.gif"><font style='font-size:10pt'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
  Act (17 CFR 240.13e-4(c))</font></p>

<div style="border:none;border-bottom:solid .25em;padding:0in 0in 1.0pt 0in">
<div style="border:none;border-bottom:solid .05em;padding:0in 0in 1.0pt 0in"><p></p></div></div><BR>
<!-- EEDocs PBStart-->

<p align="center"><font size="2" face="Serif"></font></p>

<hr noshade align="center" width="100%" size="2">

<div style="page-break-before:always"></div>
<page>
<!-- EEDocs PBEnd-->



<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><b><font style='font-size:10pt'>Item 1.01. Entry into a Material Definitive Agreement </font></b></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><font style='font-size:10pt'>On December 20, 2006, Beijing Med-Pharm Corporation, a Delaware corporation (the &#147;Company&#148;), completed a private placement (the &#147;Private Placement&#148;) of an aggregate of 3,333,306 shares of its Common Stock, par value $0.001 per share (&#147;Common Stock&#148;), and warrants exercisable for an aggregate of 666,611 shares of Common Stock. The Company sold 150 investment units (each, a &#147;Unit&#148;) in the Private Placement at a per Unit purchase price equal to $100,000. These sales were made pursuant to Subscription Agreements (the &#147;Subscription Agreements&#148;) that were entered into between the Company and certain institutional and individual accredited investors (collectively, the &#147;Investors&#148;), effective as of December 20, 2006. </font></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><font style='font-size:10pt'>Each Unit sold in the Private Placement consisted of 22,222 shares of Common Stock and a Warrant to purchase 4,444 shares of Common Stock at an exercise price of $5.625 per share, subject to adjustment (the &#147;Warrant&#148;). </font></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><font style='font-size:10pt'>Under the terms of the Subscription Agreements, the Company agreed to use its reasonable commercial efforts, subject to receipt of necessary information from the Investors, to cause a registration statement relating to the resale by the Investors of the shares of Common Stock sold in the Private Placement and the shares of Common Stock underlying the Warrants to be filed with the Securities and Exchange Commission (the &#147;SEC&#148;) within 105&nbsp;days following the closing date of the Private Placement. </font></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><font style='font-size:10pt'>The Warrants provide that the holder thereof shall have the right to acquire, at any time prior to December 20, 2011, to acquire shares of Common Stock upon the payment of $5.625 per Warrant Share to be acquired upon exercise of the Warrants. If a registration statement is not filed by the Company within 105&nbsp;days after the Closing Date or is not declared effective by the SEC on or before 180&nbsp;days after the closing date of the Private Placement (each, a &#147;Registration Default&#148;), the Company is required to reduce the exercise price of the Warrants by $0.25 for each full 30-day period for which a Registration Default exists. The then outstanding and unexercised Warrants terminate on December 20, 2011. If the Common Stock trades at a price in excess of 200% of the stated exercise price of a Warrant for any consecutive 20-day period, the Company will have the right to terminate all
unexercised Warrants of that series of Warrants by providing 45&nbsp;days&#146; prior written notice to the holders of such Warrants. The Warrants also will terminate upon the occurrence of a &#147;Change of Control,&#148; as defined in the Warrants. The Company is required to provide notice to the holders of the Warrants at least 10&nbsp;days before the closing of a &#147;Change of Control&#148; as provided in the Warrants. </font></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><font style='font-size:10pt'>The foregoing is a summary of the terms of the Subscription Agreements and the Warrants and does not purport to be complete and is qualified in its entirety by reference to the full text of the Subscription Agreements and the Warrants, forms of which are attached hereto as Exhibits 4.1 and 4.2, respectively, and incorporated by reference herein. </font></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><b><font style='font-size:10pt'>Item 3.02 Unregistered Sales of Equity Securities. </font></b></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><font style='font-size:10pt'>As described in Item 1.01 above, on December 20, 2006, the Company completed the Private Placement. Gross proceeds from the Private Placement were approximately $15 million. The Company expects to use these proceeds to further expand its business in China and for additional working capital. </font></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><font style='font-size:10pt'>Philadelphia Brokerage Corporation (the &#147;Placement Agent&#148;) acted as placement agent in the Private Placement. In connection with the Private Placement, the Company issued to the Placement Agent Warrants to purchase 450,000 shares of Common Stock, and paid the Placement Agent a placement fee equal to approximately $825,000 plus the reimbursement of certain expenses. </font></p>
<!-- EEDocs PBStart-->

<p align="center"><Font size="2" face="serif"></font></p>

<hr noshade align="center" width="100%" size="2">

<div style="page-break-before:always"></div><page>

<!-- EEDocs PBEnd-->



<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><font style='font-size:10pt'>The issuance and sale of the Common Stock and Warrants in the Private Placement was made in reliance upon the exemption from registration provided in Section 4(2) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;). The Investors are accredited investors as defined in Rule 501 of Regulation D promulgated under the Securities Act. Each of the certificates representing shares of Common Stock and each of the Warrants issued and sold in the Private Placement contain restrictive legends preventing the sale, transfer or other disposition of such shares and Warrants unless registered under the Securities Act.</font></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><b><font style='font-size:10pt'>Item</font></b><font style='font-size:10pt'>&nbsp;</font><b><font style='font-size:10pt'>9.01 Financial Statements and Exhibits. </font></b></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt;'><font style='font-size:10pt'>(c) Exhibits.</font></p>

<p align="left" style=' margin-bottom:0pt; margin-top:0pt;'><font style='font-size:10pt'>&nbsp;</font></p>


<div align=left>


  <table border="0" cellspacing=0 cellpadding=0 width="100%" style=' border-collapse:collapse;'>
    <tr>


      <td width="8%" valign=bottom >
        <p align=center style='margin-Top:0pt;margin-bottom:0pt;'><b><font style='font-size:8pt'>Exhibit</font></b></p>

        <p align=center style='margin-top:0in;margin-bottom:0pt;'><b><font style='font-size:8pt'>Number</font></b></p>
      </td>

        <td width="2%" valign=bottom >

<p align=left style='margin-Top:0pt;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td valign=bottom >

<p align=left style='margin-Top:0pt;margin-bottom:0pt;'><b><font style='font-size:8pt'>Description of Exhibit</font></b></p> </td> </tr>
    <tr>

        <td valign=top >

<p align=left style='margin-bottom:0pt;'>
<hr noshade width="100%" color="Gray" size="1"> </td>

        <td valign=top >

<p align=left style='margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td valign=top >

<p align=left style='margin-bottom:0pt;'>
<hr noshade width="100%" color="Gray" size="1"> </td> </tr>
    <tr valign="top">
      <td >
        <p align=left style='margin-Top:0pt;margin-bottom:0pt;'><font style='font-size:10pt'>4.1</font></p> </td>


      <td >
        <p align=left style='margin-Top:0pt;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>


      <td >
        <p align=left style='margin-Top:0pt;margin-bottom:0pt;'><font style='font-size:10pt'>Form of Subscription Agreement, dated December 20, 2006, by and between Beijing Med-Pharm Corporation and each of the respective Investors</font></p> </td> </tr>
    <tr valign="top">
      <td >
        <p align=left style='margin-Top:6pt;margin-bottom:0pt;'><font style='font-size:10pt'>4.2</font></p> </td>


      <td >
        <p align=left style='margin-Top:0pt;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>


      <td >
        <p align=left style='margin-Top:6pt;margin-bottom:0pt;'><font style='font-size:10pt'>Form of Warrant, dated December 20, 2006, by and between Beijing Med-Pharm Corporation and each of the respective Investors</font></p> </td> </tr></table>
</div>



<!-- EEDocs PBStart-->

<p align="center"><Font size="2" face="serif"></font></p>

<hr noshade align="center" width="100%" size="2">

<div style="page-break-before:always"></div><page>

<!-- EEDocs PBEnd-->



<p align="center" style=' margin-bottom:0pt; margin-top:8pt;'><B><font style='font-size:10PT'>SIGNATURES</font></B></p>

<p align="left" style=' margin-bottom:0pt; margin-top:8pt; text-indent:5%;'><font style='font-size:10pt'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>

<p align="left" style=' margin-bottom:0pt; margin-top:0pt;'><font style='font-size:10pt'>&nbsp;</font></p>


<div align=center>


<table border="0" cellspacing=0 cellpadding=0 width="100%" style=' border-collapse:collapse;'>
    <tr>

        <td width="49%" valign=bottom >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td width="7%" valign=bottom >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td colspan="2" valign=bottom >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font style='font-size:10PT'>BEIJING MED-PHARM CORPORATION</font></p> </td> </tr>
    <tr>

        <td width="49%" valign=bottom >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><br> <font style='font-size:10pt'>Date: December 20, 2006</font></p> </td>

        <td width="7%" valign=bottom >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td width="4%" valign=bottom >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font style='font-size:10pt'>By:&nbsp;</font></p> </td>


      <td width="40%" valign=bottom >
        <p align=left style='margin-top:0in;margin-bottom:0pt;'><br>
          <font style='font-size:10pt'>/s/&nbsp;F<font style='font-size:8pt'>RED</font>
          M. P<font style='font-size:8pt'>OWELL</font></font></p>
      </td> </tr>
    <tr>

        <td valign=top >

<p align=left style='margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td valign=top >

<p align=left style='margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td valign=top >

<p align=left style='margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td valign=top >

<p align=left style='margin-bottom:0pt;'>
<hr noshade width="100%" color="Gray" size="1"> </td> </tr>
    <tr>

        <td valign=top >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td valign=top >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>


      <td valign=top >
        <p align=left style='margin-top:0in;margin-bottom:0pt;'><font style='font-size:10pt'>Name:&nbsp;</font></p>
      </td>

        <td valign=top >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font style='font-size:10pt'>Fred M. Powell</font></p> </td> </tr>
    <tr>

        <td valign=top >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td valign=top >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font size=1>&nbsp;</font></p> </td>

        <td valign=top >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font style='font-size:10pt'>Title:</font></p> </td>

        <td valign=top >

<p align=left style='margin-top:0in;margin-bottom:0pt;'><font style='font-size:10pt'>Chief Financial Officer</font></p> </td> </tr></table>
</div>



<!-- EEDocs PBStart-->

<p align="center"><Font size="2" face="serif"></font></p>

<hr noshade align="center" width="100%" size="2">







</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b416579_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 18015}]
{"company-data": {"conformed-name": "BEIJING MED PHARM CORP", "cik": "0001281696", "assigned-sic": "5122", "irs-number": "000000000"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-32980", "film-number": "061291970"}, "business-address": {"street1": "1180 MAIN ST", "city": "COVENTRY", "state": "CT", "zip": "06238", "phone": "860-538-6630"}}
Prepared and Filed by St Ives Financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
  of Report (Date of earliest event reported):
December
  20, 2006
BEIJING MED-PHARM CORPORATION
(Exact name of registrant specified in its charter)
Delaware
(State or other jurisdiction of
incorporation)
000-51409
(Commission File Number)
20-0434726
(I.R.S. Employer Identification
No.)
600
      W. Germantown Pike, Suite 400,
Plymouth Meeting, Pennsylvania
(Address of principal executive offices)
19462
(Zip Code)
Registrant's telephone, including area code:
(610) 940-1675
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (
see
General Instruction A.2. below):
Written communications pursuant to Rule 425 under
  the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under
  the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
  Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
  Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement
On December 20, 2006, Beijing Med-Pharm Corporation, a Delaware corporation (the "Company"), completed a private placement (the "Private Placement") of an aggregate of 3,333,306 shares of its Common Stock, par value $0.001 per share ("Common Stock"), and warrants exercisable for an aggregate of 666,611 shares of Common Stock. The Company sold 150 investment units (each, a "Unit") in the Private Placement at a per Unit purchase price equal to $100,000. These sales were made pursuant to Subscription Agreements (the "Subscription Agreements") that were entered into between the Company and certain institutional and individual accredited investors (collectively, the "Investors"), effective as of December 20, 2006.
Each Unit sold in the Private Placement consisted of 22,222 shares of Common Stock and a Warrant to purchase 4,444 shares of Common Stock at an exercise price of $5.625 per share, subject to adjustment (the "Warrant").
Under the terms of the Subscription Agreements, the Company agreed to use its reasonable commercial efforts, subject to receipt of necessary information from the Investors, to cause a registration statement relating to the resale by the Investors of the shares of Common Stock sold in the Private Placement and the shares of Common Stock underlying the Warrants to be filed with the Securities and Exchange Commission (the "SEC") within 105 days following the closing date of the Private Placement.
The Warrants provide that the holder thereof shall have the right to acquire, at any time prior to December 20, 2011, to acquire shares of Common Stock upon the payment of $5.625 per Warrant Share to be acquired upon exercise of the Warrants. If a registration statement is not filed by the Company within 105 days after the Closing Date or is not declared effective by the SEC on or before 180 days after the closing date of the Private Placement (each, a "Registration Default"), the Company is required to reduce the exercise price of the Warrants by $0.25 for each full 30-day period for which a Registration Default exists. The then outstanding and unexercised Warrants terminate on December 20, 2011. If the Common Stock trades at a price in excess of 200% of the stated exercise price of a Warrant for any consecutive 20-day period, the Company will have the right to terminate all
unexercised Warrants of that series of Warrants by providing 45 days' prior written notice to the holders of such Warrants. The Warrants also will terminate upon the occurrence of a "Change of Control," as defined in the Warrants. The Company is required to provide notice to the holders of the Warrants at least 10 days before the closing of a "Change of Control" as provided in the Warrants.
The foregoing is a summary of the terms of the Subscription Agreements and the Warrants and does not purport to be complete and is qualified in its entirety by reference to the full text of the Subscription Agreements and the Warrants, forms of which are attached hereto as Exhibits 4.1 and 4.2, respectively, and incorporated by reference herein.
Item 3.02 Unregistered Sales of Equity Securities.
As described in Item 1.01 above, on December 20, 2006, the Company completed the Private Placement. Gross proceeds from the Private Placement were approximately $15 million. The Company expects to use these proceeds to further expand its business in China and for additional working capital.
Philadelphia Brokerage Corporation (the "Placement Agent") acted as placement agent in the Private Placement. In connection with the Private Placement, the Company issued to the Placement Agent Warrants to purchase 450,000 shares of Common Stock, and paid the Placement Agent a placement fee equal to approximately $825,000 plus the reimbursement of certain expenses.
The issuance and sale of the Common Stock and Warrants in the Private Placement was made in reliance upon the exemption from registration provided in Section 4(2) of the Securities Act of 1933, as amended (the "Securities Act"). The Investors are accredited investors as defined in Rule 501 of Regulation D promulgated under the Securities Act. Each of the certificates representing shares of Common Stock and each of the Warrants issued and sold in the Private Placement contain restrictive legends preventing the sale, transfer or other disposition of such shares and Warrants unless registered under the Securities Act.
Item
9.01 Financial Statements and Exhibits.
(c) Exhibits.
Exhibit
Number
Description of Exhibit
4.1
Form of Subscription Agreement, dated December 20, 2006, by and between Beijing Med-Pharm Corporation and each of the respective Investors
4.2
Form of Warrant, dated December 20, 2006, by and between Beijing Med-Pharm Corporation and each of the respective Investors
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BEIJING MED-PHARM CORPORATION
Date: December 20, 2006
By:
/s/ F
RED
M. P
OWELL
Name:
Fred M. Powell
Title:
Chief Financial Officer